You're Gaining Breast Tissue and Nobody's Told You Why. It's Genetic.

The AR gene codes for the androgen receptor, the protein that sits on your cells and listens for testosterone. When testosterone binds to this receptor, your body responds: your muscles grow, your metabolism shifts, your facial hair develops, your voice deepens. The androgen receptor is the literal switch that makes you respond as a male.

The AR gene contains a repeating sequence of the letters CAG. The longer this repeat, the less sensitive your androgen receptor becomes. A man with a short CAG repeat (16-18 copies) has a very responsive androgen receptor that amplifies testosterone’s signals throughout his body. A man with a longer CAG repeat (24-26 copies or more) has a less responsive androgen receptor. This means even with normal testosterone levels, his cells simply don’t respond as strongly to that testosterone. His body shifts toward a more female-typical fat distribution pattern and breast tissue development.

If you carry longer CAG repeats, your testosterone is literally speaking to your cells more quietly than it should. Your cells don’t hear the signal to build muscle, maintain male-pattern fat distribution, or suppress breast tissue growth. So your body follows a more female-typical development program instead, even though your testosterone numbers look fine on bloodwork.

Your body doesn’t just produce testosterone and let it float freely in your bloodstream. Instead, most of it gets bound to a carrier protein called SHBG (sex hormone-binding globulin). Only the unbound testosterone, the free testosterone, can actually interact with your androgen receptors. The rest is locked up and biologically inactive.

Your SHBG gene has variants that affect how much SHBG your body produces. People carrying certain variants at rs6259 and rs1799941 produce higher levels of SHBG. With higher SHBG, more of your testosterone gets bound up and locked away, leaving less free testosterone available to activate your androgen receptors. Your total testosterone number on a bloodwork panel might look normal, but your free testosterone is low because most of it is bound. Roughly 30-40% of men carry variants that increase SHBG production.

This is particularly relevant to gynecomastia because while your bound testosterone is inactive, your estrogen circulates freely. So you end up with a ratio problem: plenty of locked-up testosterone, plenty of active estrogen, and your body shifts into an estrogenic state. Breast tissue grows. Your muscles don’t grow as readily despite training. Your motivation and libido suffer.

Your body has an enzyme called aromatase, coded by the CYP19A1 gene. Aromatase’s job is to convert testosterone into estrogen. This is not a pathological process; it’s completely normal. Your body needs some estrogen even as a male, for bone health, mood regulation, and sexual function. The problem arises when you convert too much testosterone into estrogen, or when you have genetic variants that make your aromatase work overtime.

The CYP19A1 gene has several common variants that affect aromatase activity. Some variants increase aromatase expression, meaning your cells produce more of this enzyme and convert more testosterone into estrogen. If you carry variants that increase aromatase activity, you’re converting a larger fraction of your testosterone into estrogen before it can ever reach your androgen receptors and build muscle or suppress breast tissue growth. This creates a net effect of relative estrogen dominance even if your absolute estrogen number is not unusually high.

You experience this as stubborn chest tissue, a softer body composition despite training, and difficulty building muscle mass. Your testosterone is being converted to estrogen before your body can use it for male-typical development. The more aromatase activity you have, the more pronounced this pattern becomes.

The COMT gene codes for an enzyme that breaks down dopamine and norepinephrine. The COMT Val158Met variant determines how quickly you clear these neurotransmitters. People with the Val/Val genotype are ‘fast’ metabolizers; they break down dopamine quickly. People with the Met/Met genotype are ‘slow’ metabolizers; they maintain dopamine longer. Roughly 25% of people of European ancestry are homozygous slow metabolizers.

This matters for gynecomastia because dopamine and catecholamine metabolism directly affect androgen receptor expression and testosterone sensitivity. People who are slow COMT metabolizers maintain higher dopamine levels, which can actually suppress androgen receptor expression and reduce your tissues’ responsiveness to testosterone. If you’re a slow COMT metabolizer, you may have normal testosterone and normal androgen receptors, but your dopamine is suppressing the androgen receptor signaling that would normally prevent breast tissue growth. The net effect is relative androgen insensitivity even though your receptors themselves are fine.

You might experience this as difficulty building muscle despite training, lower libido, and a softer body composition. Your body isn’t responding to testosterone signaling as effectively as it should because your elevated dopamine is muting the androgen receptor response.

The VDR gene codes for the vitamin D receptor, a protein that allows your cells to respond to vitamin D. Vitamin D is not just about bone health; it’s a hormone that regulates the expression of hundreds of genes, including genes involved in androgen receptor expression and testosterone metabolism. If your VDR doesn’t work optimally, your cells can’t properly process vitamin D signals, and your hormonal regulation suffers.

The VDR Fok1 variant is the most studied. People carrying the short allele have a more active VDR; people carrying the long allele have a less active VDR. If you carry VDR variants associated with lower vitamin D receptor activity, your cells can’t fully respond to vitamin D, even if your 25-OH vitamin D blood level is normal. This impairs your androgen receptor expression and testosterone sensitivity at the cellular level. It also increases aromatase expression and estrogen conversion. The result is a hormonal environment that favors estrogen and breast tissue development.

You experience this as insufficient response to vitamin D supplementation, persistent hormone imbalance despite adequate sun exposure or oral vitamin D, and difficulty building muscle even with training and normal testosterone levels. Your cells simply aren’t receiving the vitamin D signal that would otherwise enhance your androgen receptor responsiveness.

The MTHFR gene codes for an enzyme that is crucial for methylation, the process by which your body adds methyl groups to molecules to activate or deactivate them. Methylation is essential for hormone metabolism, including the metabolism of estrogen and the synthesis of nitric oxide, which regulates vascular function and sexual function.

The MTHFR C677T variant reduces the enzyme’s efficiency by 35-40%. Roughly 40% of people of European ancestry carry at least one copy of this variant. If you have MTHFR C677T, your cells methylate less efficiently, which impairs estrogen metabolism and allows estrogen to accumulate in your tissues rather than being properly cleared. It also reduces nitric oxide synthesis, which impairs vascular function and further compromises androgen receptor signaling in tissues that depend on good blood flow. Your body becomes less capable of clearing excess estrogen and more estrogenic overall.

You experience this as progressive breast tissue development, difficulty losing body fat in typical male-pattern areas, lower energy, and sometimes brain fog or mood changes. Your body isn’t clearing estrogen efficiently, so it accumulates. Combined with the other genes on this list, MTHFR variants dramatically increase gynecomastia risk.